CRNX (STOCKS)
Crinetics Pharmaceuticals, Inc.
$35.120000
+0.650000 (+1.89%)
Prev close: $34.470000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Scott R. Struthers
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,703.06M
- Employees
- 437
- P/E (TTM)
- -6.84
- P/B (TTM)
- 2.83
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
13
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-1.23 | $-1.26 | +0.0317 | +2.51% |
|
Dec 2025 (Q4)
|
$-1.29 | $-1.39 | +0.1048 | +7.51% |
|
Sep 2025 (Q3)
|
$-1.38 | $-1.28 | -0.0993 | -7.75% |
|
Jun 2025 (Q2)
|
$-1.23 | $-1.12 | -0.1096 | -9.78% |
Financial Statements
| Revenues | $18.07M |
| Benefits Costs and Expenses | $410.14M |
| Cost Of Revenue | $1.28M |
| Costs And Expenses | $591.92M |
| Nonoperating Income/Loss | $49.53M |
| Operating Expenses | $562.54M |
| Depreciation and Amortization | $4.13M |
| Research and Development | $355.90M |
| Operating Income/Loss | -$545.74M |
| Income/Loss From Continuing Operations After Tax | -$496.39M |
| Income/Loss From Continuing Operations Before Tax | -$392.07M |
| Net Income/Loss | -$496.39M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$496.39M |
| Net Income/Loss Available To Common Stockholders, Basic | -$496.39M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$5.13 |
| Diluted Earnings Per Share | -$5.13 |
| Basic Average Shares | 292,455,000 |
| Diluted Average Shares | 292,455,000 |
| Assets | $1.40B |
| Current Assets | $1.32B |
| Cash | $1.30B |
| Inventory | $3.06M |
| Other Current Assets | $19.35M |
| Noncurrent Assets | $78.91M |
| Fixed Assets | $13.50M |
| Other Non-current Assets | $65.41M |
| Liabilities | $120.68M |
| Current Liabilities | $71.09M |
| Accounts Payable | $12.88M |
| Other Current Liabilities | $58.21M |
| Noncurrent Liabilities | $49.59M |
| Equity | $1.28B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.28B |
| Liabilities And Equity | $1.40B |
| Net Cash Flow From Operating Activities | -$414.17M |
| Net Cash Flow From Operating Activities, Continuing | -$414.17M |
| Net Cash Flow From Investing Activities | $7.51M |
| Net Cash Flow From Investing Activities, Continuing | $7.51M |
| Net Cash Flow From Financing Activities | $426.05M |
| Net Cash Flow From Financing Activities, Continuing | $426.05M |
| Net Cash Flow | $19.39M |
| Net Cash Flow, Continuing | $19.39M |
| Comprehensive Income/Loss | -$499.64M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$499.64M |
| Other Comprehensive Income/Loss | -$3.26M |
| Other Comprehensive Income/Loss Attributable To Parent | -$3.26M |